Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity now available at the Rutherford Cancer Centre North West in Liverpool.
Rutherford Health plc today announced that it has commenced coronavirus antibody testing for staff and patients throughout its network of Rutherford Cancer Centres.
Tests are being carried out at the centres in Reading, Newport (South Wales), Bedlington, Northumberland and Liverpool and are being processed at a laboratory in Neasden, Middlesex. Data from the testing is being provided to Government ministers and advisers on testing.
Professor Karol Sikora, chief medical officer, Rutherford Health, said: “It is vital that patients are as safe as possible when they are being treated and testing will help enormously. It is also hugely important that medical and nursing staff know their status as they are mixing with patients on a daily basis.
“Our patients include those referred by the NHS and we are engaging in dialogue with the government over the data from our testing.”
Mike Moran, chief executive of Rutherford Health, said: “We were able to secure testing kits from South Korea which had been used successfully in Germany. Our primary concern is ensuring the safety of patients and staff.”
Clinical staff at the Rutherford Cancer Centres
If you'd like to speak to us about any of the treatments we offer please don’t hesitate to get in touch. Call us on 0800 210 0402 or
© Copyright Rutherford Health Plc 2017 - 2022
All rights Reserved